Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 594 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

USPTO grants NOA to Cynapsus APL-130277

Fast-acting APL-130277 is a thin film sublingual formulation of apomorphine, which is designed for use in the rescue of Parkinson’s patients from "off" episodes in which the patients

Theravance initiates TD-4208 Phase 2b dose ranging study

Theravance leveraged its multivalent approach of drug design to discover the investigational inhaled long-acting muscarinic antagonist TD-4208. Theravance research and early clinical development senior vice president Mathai Mammen